Fig. 8.

Overlapping distributions of FLI in cervical spinal cord after intradermal injections of SLIGRL-NH₂ (50 μg/5 μl) or 5-HT (47 nmol/5 μl) in nape of neck. A, photomicrograph of midcervical section showing FLI elicited by PAR-2 agonist. B, drawing of cervical dorsal horn compiling FLI from one section each from mice injected with PAR-2 agonist (•) or 5-HT (▴) in nape of neck. C, mean counts of FLI from mice receiving intradermal PAR-2 agonist (blue bar; n = 6), 5-HT (red bar; n = 6), or saline (white bar; n = 4). *, p < 0.05 significantly different versus groups receiving PAR-2 agonist and 5-HT (counts for PAR-2 agonist versus 5-HT not significantly different).